Patient characteristics and process factors associated with antipsychotic polypharmacy in a nationwide sample of psychiatric inpatients in Italy

Pharmacoepidemiology and Drug Safety

Volumn 20, Issue 5, 2011, Pages 441-449

  Santone, Giovanni ^a   Bellantuono, Cesario ^a   Rucci, Paola ^b   Picardi, Angelo ^c   Preti, Antonio ^d   de Girolamo, Giovanni ^e  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d UNIVERSITY OF CAGLIARI   (Italy)

^e IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

Author keywords

Antipsychotics; Polypharmacy; Process of care; Psychiatric inpatients

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HOSPITAL PATIENT; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; SCHIZOPHRENIA; SCORING SYSTEM; STANDARDIZATION;

ADULT; ANTIPSYCHOTIC AGENTS; DRUG PRESCRIPTIONS; DRUG UTILIZATION; HEALTH CARE SURVEYS; HOSPITALS, PSYCHIATRIC; HUMANS; ITALY; MALE; MENTAL DISORDERS; PHYSICIAN'S PRACTICE PATTERNS; POLYPHARMACY; SOCIOECONOMIC FACTORS;

EID: 79955126232     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2083     Document Type: Article

References (60)

1. Mojtabai R, Olfson M.National trends on psychotropic medication polypharmacy in office-based psychiatry.Arch Gen Psychiatry 2010;67:26-36.
2. Broekema WJ, de Groot IW, van Harten PN.Simultaneous prescribing of atypical antipsychotics and anticholinergics-A European study.Pharm World Sci 2007;29:126-130.
3. Kreyenbuhl JA, Valenstein M, McCarthy JF, Ganoczy D, Blow FC.Long-term antipsychotic polypharmacy in the VA health system: Patient characteristics and treatment patterns.Psychiatr Serv 2007;58:489-495.
4. Lerma-Carrillo I, de Pablo Brühlmann S, del Pozo ML, Pascual-Pinazo F, Molina JD, Baca-García E.Antipsychotic polypharmacy in patients with schizophrenia in a brief hospitalization unit.Clin Neuropharmacol 2008;31:319-332.
5. Morrato EH, Dod S, Oderda G, Haxby DG, Allen R, Valuck RJ, on behalf of the Medical Pharmacotherapy Research Consortium.Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: Experience in a multisite Medicaid population, 1998-2003.Clin Ther 2007;29:183-195.
6. Biancosino B, Barbui C, Marmai L, Donà S, Grassi L.Determinants of antipsychotic polypharmacy in psychiatric inpatients: A prospective study.Int Clin Psychopharmacol 2005;20:305-309.
7. Mauri MC, Regispani F, Beraldo S, et al.Patterns of clinical use of antipsychotics in hospitalized psychiatric patients.Prog Neuropsychopharmacol Biol Psychiatry 2005;29:957-963.
8. Sim K, Su A, Fujii S, et al.Antipsychotic polypharmacy in patients with schizophrenia: A multicentre comparative study.Br J Clin Pharmacol 2004;58:178-183.
9. Procyshyn RM, Kennedy NB, Tse G, Thompson B.Antipsychotic polypharmacy: A survey of discharge from a tertiary care psychiatric institution.Can J Psychiatry 2001;46:334-339.
10. Frye MA, Ketter TA, Leverich GS, et al.Increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study.J Clin Psychiatry 2000;61:9-15.
11. Verdoux H, Tournier M, Bégaud B.Antipsychotic prescribing trends A review of pharmaco-epidemiological studies.Acta Psychiatr Scand 2010;121:4-10.
12. Sankaranarayanan J, Puumala SE.Antipsychotic use at adult ambulatory care visits by patients with mental health disorders in the United States, 1996-2003: National estimates and associated factors.Clin Ther 2007;4:723-741.
13. Jaffe AB, Levine J.Antipsychotic medication co-prescribing in a large state hospital system.Pharmacoepidemiol Drug Saf 2003;12:41-48.
14. Barbui C, Nosé M, Mazzi MA, et al.Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries.Int Clin Psychopharmacol 2006;21:355-362.
15. Ganguly R, Kotzan JA, Miller S, Kennedy K, Martin BC.Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.J Clin Psychiatry65:1377-1388.
16. Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S.Antipsychotic combinations vs. monotherapy in schizophrenia: A meta-analysis of randomized controlled trials.Schizophr Bull 2009;35:445-457.
17. Freudenreich O, Goff DC.Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of concurrent combinations.Acta Psychiatr Scand 2002;106:323-330.
18. Pandurangi AK, Dalkilic A.Polypharmacy with second-generation antipsychotics: A review of evidence.J Psychiatr Pract 2008;14:345-367.
19. National Institute for Health and Clinical Excellence.Schizophrenia. Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Update).National Institute for Health and Clinical Excellence: London, 2009.
20. Taylor DM, Smith L.Augmentation of clozapine with a second antipsychotic-A meta-analysis of randomized, placebo-controlled studies.Acta Psychiatr Scand 2009;119:419-425.
21. Kreyenbuhl J, Marcus SC, West JC, Wilk J, Olfson J.Adding or switching antipsychotic medications in treatment-resistant schizophrenia.Psychiatr Serv 2007;58:983-990.
22. Centorrino F, Goren JL, Hennen J, Salvatore P, Kelleher JP, Baldessarini RJ.Multiple versus single antipsychotic agents for hospitalized psychiatric patients: Case-control study of risks versus benefits.Am J Psychiatry 2004;161:700-706.
23. Carnahan RM, Lund BC, Perry PJ, Chrischilles EA.Increased risk of extrapyramidal side-effects treatment associated with atypical antipsychotic polytherapy.Acta Psychiatr Scand 2006;113:135-141.
24. Correll CU, Frederickson AM, Kane JM, Manu P.Does antipsychotic polypharmacy increase the risk for metabolic syndrome?Schizophr Res 2007;89:91-100.
25. Waddington JL, Youssef HA, Kinsella A.Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study.Br J Psychiatry 2008;173:325-329.
26. Weinmann S, Read J, Aderhold V.Influence of antipsychotics on mortality in schizophrenia: Systematic review.Schizophr Res 2009;113:1-11.
27. Kroken RA, Johnesn E, Ruud T, Wentzel-Larsen T, Jørgensen HJ.Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross sectional study.BMC Psychiatry 2009;9:24.
28. Muscettola G, Casiello M, Bollini P, Sebastiani G, Pampallona S, Tognoni G.Pattern of therapeutic intervention and role of psychiatric settings: A survey in two regions in Italy.Acta Psychiatr Scand 1987;75:55-61.
29. Lelliott P, Paton C, Harrington M, Konsolaki M, Sensky T, Okocha C.The influence of patient variables on polypharmacy and combined high dose of antipsychotic drugs prescribed for in-patients.Psychiatr Bull R Coll Psychiatr 2002;26:411-414.
30. Tapp A, Wood EA, Secrest L, Erdmann J, Cubberley L, Kilzieh N.Combination antipsychotic therapy in clinical practice.Psychiatr Serv 2003;54:55-59.
31. Ananth J, Parameswaran S, Gunatilake S.Antipsychotic polypharmacy.Curr Pharm Des 2004;10:2231-2238.
32. de Girolamo G, Barbato A, Bracco R, et al.Characteristics and activities of acute psychiatric in-patient facilities: National survey in Italy.Br J Psychiatry 2007;191:170-177.
33. Preti A, Rucci P, Santone G, et al.Patterns of admission to acute psychiatric inpatient facilities: A national survey in Italy.Psychol Med 2009;39:485-496.
34. World Health Organization.Tenth Revision of the International Classification of Diseases and Related Health Problems (ICD-10).WHO Press: Geneva, 1992.
35. de Girolamo G, Bellini M, Bocchia S, Ruggeri M.Brief Psychiatric Rating Scale versione 4.0 "ampliata" (BPRS 4.0).Epidemiol Psichiatr Soc 1995;4:69-85.
36. Santone G, de Girolamo G, Falloon I, et al.The process of care in residential facilities: A national survey in Italy.Soc Psychiatry Psychiatr Epidemiol 2005;40:540-550.
37. Goldstein H.Multilevel Statistical Models.Edward Arnold: London, 1995.
38. Snijders T, Bosker R.Multilevel Analysis.Sage: Thousand Oaks, CA, 1999.
39. de Girolamo G, Bassi M, Neri G, Ruggeri M, Santone G, Picardi A.Characteristics and activities of acute psychiatric in-patient facilities: National survey in Italy.Eur Arch Psychiatry Clin Neurosci 2007;257:83-91.
40. Tibaldi G, Munizza C, Bollini P, Pirfo E, Punzo F, Gramaglia F.L'utilizzo dei neurolettici nei servizi psichiatrici italiani: I risultati di una ricerca in Piemonte.Annali di Freniatria 2004;3:3-9.
41. Tomasi R, de Girolamo G, Santone G, et al.The prescription of psychotropic drugs in psychiatric residential facilities: A national survey in Italy.Acta Psychiatr Scand 2006;113:212-223.
42. Lerner V, Libov I, Kotler M, Strous RD.Combination of "atypical" antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder.Prog Neuropsychopharmacol Biol Psychiatry 2004;28:89-98.
43. Centorrino F, Fogarty KV, Sani G, et al.Use of combination of antipsychotics: McLean Hospital inpatients, 2002.Hum Psychopharmacol 2005;20:485-492.
44. Atik L, Erdogan A, Karahmet E, et al.Antipsychotic prescriptions in an university hospital outpatient population in Turkey. A retrospective database analysis, 2005-2006.Prog Neuropsychopharmacol Biol Psychiatry 2008;32:968-974.
45. Bellantuono C, Barraco A, Rossi A, Goetz I.The management of bipolar mania: A national survey of baseline data from the EMBLEM study in Italy.BMC Psychiatry 2007;7:33.
46. Sernyak MJ, Rosenheck R.Clinicians' reasons for antipsychotic coprescribing.J Clin Psychiatry 2004;65:1597-1600.
47. Harrington M, Lelliott P, Paton C, Konsolaki M, Sensky T, Okocha C.Variation between services in polypharmacy and combined high dose of antipsychotic drugs prescribed for in-patients.Psychiatr Bull R Coll Psychiatr 2002;26:418-420.
48. Taylor D, Mir S, Mace S, Whiskey E.Co-prescribing of atypical and typical antipsychotics-Prescribing sequences and documented outcome.Psychiatr Bull R Coll Psychiatr 2002;26:170-172.
49. Ito H, Koyama A, Higuchi T.Polypharmacy and excessive dosing: Psychiatrists' perceptions of antipsychotic drug prescription.Br J Psychiatry 2005;187:243-247.
50. Remington G, Shammi CM, Sethna R, Lawrence R.Antipsychotic dosing patterns for schizophrenia in three treatment settings.Psychiatr Serv 2001;52:96-98.
51. Janssen B, Weinmann S, Berger M, Gaebel W.Validation of polypharmacy process measures in inpatient schizophrenia care.Schizophr Bull 2004;30:1023-1033.
52. Weinmann S, Janssen B, Gaebel W.Guideline adherence in medication management of psychotic disorders: An observational multisite hospital study.Acta Psychiatr Scand 2005;112:18-25.
53. Paton C, Lelliott P.The use of prescribing indicators to measure the quality of care in psychiatric inpatients.Qual Saf Health Care 2004;13:40-45.
54. Covell NH, Jackson CT, Evans AC, et al.Antipsychotic prescribing practices in Connecticut's public mental health system: Rates of changing medication and prescribing styles.Schizophr Bull 2002;28:17-29.
55. Harrington M, Lelliott P, Paton C, Okocha C, Duffett R, Sensky T.The results of a multi-centre audit of the prescribing of antipsychotic drugs for in-patients in the UK.Psychiatr Bull R Coll Psychiatr 2002;26:414-418.
56. Hughes CM, Lapane LL, Mor V.Influence of facility characteristics on use of antipsychotic medications in nursing home.Med Care 2000;38:1164-1173.
57. Rochon PA, Stukel TA, Bronskill SE, et al.Variation in nursing home antipsychotic prescribing rates.Arch Intern Med 2007;167:676-683.
58. Bollini P, Pampallona S, Tibaldi G, Bianco M, Nieddu S, Munizza C.Structural and organizational determinants of quality of care in patients with schizophrenia in Italy.J Nerv Ment Dis 2008;196:923-926.
59. Castle NG, Hanlon JT, Handler SM.Results of a longitudinal analysis of national data to examine relationships between organizational and market characteristics and changes in antipsychotic prescribing in US nursing homes from 1996 through 2006.Am J Geriatr Pharmacother 2009;7:143-150.
60. Aparasu RR, Jano E, Bhatara V.Concomitant antipsychotic prescribing in US patient settings.J Soc Adm Ther 2009;5:234-241.